Compare ONON & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONON | WST |
|---|---|---|
| Founded | 2010 | 1923 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 20.2B |
| IPO Year | 2021 | N/A |
| Metric | ONON | WST |
|---|---|---|
| Price | $48.14 | $279.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 10 |
| Target Price | $62.75 | ★ $346.78 |
| AVG Volume (30 Days) | ★ 9.9M | 661.6K |
| Earning Date | 11-12-2025 | 10-23-2025 |
| Dividend Yield | N/A | ★ 0.31% |
| EPS Growth | ★ 74.51 | 0.17 |
| EPS | 0.84 | ★ 6.75 |
| Revenue | ★ $3,607,815,596.00 | $3,017,900,000.00 |
| Revenue This Year | $31.86 | $7.01 |
| Revenue Next Year | $22.90 | $6.20 |
| P/E Ratio | $57.01 | ★ $41.51 |
| Revenue Growth | ★ 33.26 | 4.92 |
| 52 Week Low | $34.38 | $187.43 |
| 52 Week High | $64.05 | $348.90 |
| Indicator | ONON | WST |
|---|---|---|
| Relative Strength Index (RSI) | 70.87 | 55.28 |
| Support Level | $43.17 | $269.08 |
| Resistance Level | $43.57 | $285.54 |
| Average True Range (ATR) | 1.70 | 7.15 |
| MACD | 0.77 | 1.29 |
| Stochastic Oscillator | 99.75 | 82.62 |
On Holding AG is a premium performance sports brand rooted in technology, design, and impact. Its shoes, apparel, and accessories products are designed predominantly for athletic use, casual, or leisure purposes. It does not manufacture the products or the raw materials and relies instead on third-party suppliers and contract manufacturers. Geographically, it derives a majority of its revenue from the Americas and rest from Europe, Middle East and Africa and Asia-Pacific region.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.